← All trials
NCT02947685
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2017
- Primary completion
- Oct 31, 2020
- Completion date
- Aug 31, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 496
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Alliance Foundation TrialsLead sponsor
- PfizerCollaborator
- Fondazione MichelangeloCollaborator
- PrECOG, LLC.Collaborator
- INC ResearchCollaborator
- SOLTI Breast Cancer Research GroupCollaborator
- The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)Collaborator
- Mastering Breast Cancer Initiative, LLCCollaborator
- Washington State UniversityCollaborator
- Mayo ClinicCollaborator
- Ohio State UniversityCollaborator
- Alliance Foundation TrialsStudy chair
- German Breast Group Forschungs GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.